dapsone has been researched along with epiroprim in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 8 (72.73) | 18.2507 |
2000's | 2 (18.18) | 29.6817 |
2010's | 1 (9.09) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Queener, SF | 1 |
Bera, S; Mondal, D | 1 |
Dankert, W; Hartman, PG; Mehlhorn, H; Then, RL | 1 |
Arsenijevic, D; Chang, HR; Comte, R; Pechère, JC; Polak, A; Then, RL | 1 |
Foy, J; Steele, P; Walzer, PD; White, M | 1 |
Allegra, CJ; Kovacs, JA; Martinez, A | 1 |
Angehrn, P; Hartman, PG; Locher, HH; Schlunegger, H; Then, RL | 1 |
Brun-Pascaud, M; Chau, F; Derouin, F; Garry, L; Girard, PM; Jacobus, D | 1 |
Dhople, AM | 3 |
2 review(s) available for dapsone and epiroprim
Article | Year |
---|---|
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
Topics: Animals; Drug Design; Humans; Immunosuppression Therapy; Molecular Structure; Opportunistic Infections; Pneumonia, Pneumocystis; Structure-Activity Relationship | 1995 |
Insights of synthetic analogues of anti-leprosy agents.
Topics: Humans; Leprostatic Agents; Leprosy; Structure-Activity Relationship | 2019 |
9 other study(ies) available for dapsone and epiroprim
Article | Year |
---|---|
A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Dapsone; Drug Therapy, Combination; Female; Folic Acid Antagonists; Male; Mice; Mice, Inbred Strains; Mice, Nude; Mice, SCID; Pilot Projects; Pneumocystis; Pneumocystis Infections; Pyrimethamine; Rats; Rats, Nude; Sodium Chloride; Sulfadiazine; Toxoplasma; Toxoplasmosis, Animal; Trimethoprim | 1995 |
Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii.
Topics: Animals; Dapsone; Drug Synergism; Female; Folic Acid Antagonists; Mice; Toxoplasma; Toxoplasmosis, Animal; Trimethoprim; Uracil | 1994 |
Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.
Topics: AIDS-Related Opportunistic Infections; Animals; Dapsone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Folic Acid Antagonists; Immunosuppression Therapy; Male; Pneumonia, Pneumocystis; Rats; Rats, Sprague-Dawley; Sulfamethoxazole; Trimethoprim | 1993 |
Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice.
Topics: Acute Disease; Administration, Oral; Animals; Anti-Infective Agents; Antiprotozoal Agents; Dapsone; Drug Therapy, Combination; Folic Acid Antagonists; Half-Life; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Mice; Mice, Inbred BALB C; Sulfadiazine; Toxoplasmosis, Animal; Trimethoprim | 1996 |
Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone.
Topics: Animals; Dapsone; Drug Combinations; Folic Acid Antagonists; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Mice; Microbial Sensitivity Tests; Sepsis; Trimethoprim | 1996 |
Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.
Topics: Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Dapsone; Drug Therapy, Combination; Folic Acid Antagonists; Immunosuppression Therapy; Pneumocystis Infections; Proguanil; Pyrimethamine; Rats; Rats, Wistar; Tetrahydrofolate Dehydrogenase; Toxoplasma; Toxoplasmosis, Animal; Trimethoprim | 1996 |
In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae.
Topics: Cell-Free System; Dapsone; Folic Acid Antagonists; Leprostatic Agents; Microbial Sensitivity Tests; Mycobacterium leprae; Trimethoprim | 1999 |
Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans.
Topics: Anti-Bacterial Agents; Dapsone; Drug Therapy, Combination; Folic Acid Antagonists; Humans; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Tetrahydrofolate Dehydrogenase; Trimethoprim | 2001 |
In vivo activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with dapsone, against Mycobacterium leprae.
Topics: Administration, Oral; Animals; Armadillos; Dapsone; Drug Synergism; Female; Folic Acid Antagonists; Leprostatic Agents; Mice; Mice, Inbred BALB C; Mycobacterium leprae; Trimethoprim | 2002 |